Zhitong Finance App News, Yingtai Healthcare (01501) issued an announcement. The board of directors has reviewed and approved the issuance of A-shares to build a dual capital operation platform, build a dual capital operation platform, broaden financing channels, optimize the company's capital structure, enhance overall competitiveness, and achieve long-term steady development of the company.
Stock type: RMB common shares (A shares), each with a face value of RMB 1.00. A-shares that will be traded in RMB and listed on the Shenzhen Stock Exchange's GEM are in the same category as the existing issued H shares listed on the Stock Exchange. A shares will enjoy the same status as existing H shares listed on the Stock Exchange, with the same face value and the same voting, dividend and asset return rights.
The total number of RMB common shares (A shares) to be publicly issued this time does not exceed 37.2706 million A shares (excluding additional A shares issued due to the exercise of the over-allotment option), accounting for no more than 17.65% of the total issued share capital of the Company on the date of this announcement, and no more than 15% of the total issued share capital of the Company after the expansion of the allocation and issuance of A shares. These issuances are all new shares issued publicly, and do not involve shareholders' public sale of shares. The Company and the lead underwriter may use the over-allotment option, and the number of A-shares issued using the over-allotment option shall not exceed 15% of the proposed number of A shares to be issued (before the over-allotment option is exercised). The final number of A shares to be issued shall be determined by the shareholders in agreement with the board of directors authorized by the Company's shareholders' meeting and the sponsoring agency (lead underwriter) within the limits approved by the Shenzhen Stock Exchange and registered with the consent of the China Securities Regulatory Commission, according to specific circumstances.
Assuming that the over-allotment option is fully exercised and there are no other changes in the Company's issued share capital, the maximum number of A shares to be issued is 42.8612 million shares, accounting for approximately 20.29% of the total issued share capital of the Company on the date of this announcement and 16.87% of the total issued share capital of the Company after allotment and expansion of the issuance of A shares.
The issue price is determined by means of an inquiry. Shareholders at the shareholders' meeting of the Company authorize the board of directors and lead underwriters to determine the issue price through preliminary inquiries; or determine the issuance price through cumulative tenders and inquiries after the initial inquiry determines the issuance price range.
The directors believe that the issuance of A-shares will enable the Company to build a dual capital operation platform, build a dual capital operation platform, give full play to the outstanding advantages of abundant liquidity and diversified financing channels in the A-share capital market, and support the development and industrial layout of the company's core medical device business. On the one hand, this A-share offering can raise sufficient capital to focus on core technology research and development, product pipeline expansion and industrial ecosystem integration to continuously consolidate technical barriers and product competitiveness; on the other hand, it will help further enhance brand influence and customer trust, deepen the domestic industry market layout, and optimize the corporate governance structure and level of information disclosure. With the H+A listing structure, the company will effectively broaden financing space, optimize capital structure, enhance overall competitiveness, seize development opportunities in the medical device industry, consolidate its leading position in the industry, and achieve long-term steady development.